Nuwellis, Inc. (NUWE)
NASDAQ: NUWE · Real-Time Price · USD
3.810
-0.080 (-2.06%)
At close: Nov 19, 2026, 4:00 PM EST
3.520
-0.290 (-7.61%)
After-hours: Nov 19, 2026, 4:56 PM EST
Nuwellis Revenue
Nuwellis had revenue of $2.21M in the quarter ending September 30, 2026, a decrease of -0.23%. This brings the company's total for the last twelve months to $9.01M, up 10.28% year-over-year. In the year 2025, Nuwellis had annual revenue of $8.27M, down -5.38%. That makes Nuwellis the 37,868th largest company in the world by revenue and 4,975th in the United States.
Revenue (ttm)
$9.01M
Revenue Growth
+10.28%
P/S Ratio
0.18
Revenue / Employee
$237,053
Employees
38
Market Cap
1.54M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.27M | -470.00K | -5.38% |
| Dec 31, 2024 | 8.74M | -124.00K | -1.40% |
| Dec 31, 2023 | 8.86M | 321.00K | 3.76% |
| Dec 31, 2022 | 8.54M | 622.00K | 7.85% |
| Dec 31, 2021 | 7.92M | 480.00K | 6.45% |
| Dec 31, 2020 | 7.44M | 1.93M | 35.02% |
| Dec 31, 2019 | 5.51M | 513.00K | 10.26% |
| Dec 31, 2018 | 5.00M | 1.45M | 40.67% |
| Dec 31, 2017 | 3.55M | 2.26M | 175.64% |
| Dec 31, 2016 | 1.29M | 1.23M | 2,084.75% |
| Dec 31, 2015 | 59.00K | -236.00K | -80.00% |
| Dec 31, 2014 | 295.00K | 236.00K | 400.00% |
| Dec 31, 2013 | 59.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | 407.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baird Medical Investment Holdings | 24.49M |
| Vivos Therapeutics | 20.53M |
| Beyond Air | 8.19M |
| INVO Fertility | 8.00M |
| VolitionRx | 3.44M |
| 20/20 Biolabs | 2.00M |
| Co-Diagnostics | 858.89K |
| Nexalin Technology | 277.31K |
NUWE News
- 9 hours ago - Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric Patients - GlobeNewsWire
- 3 days ago - Nuwellis Slides: Investor presentation - Filings
- 7 days ago - Nuwellis Earnings Call Transcript: Q3 2026 - Transcripts
- 7 days ago - Nuwellis Earnings release: Q3 2026 - Filings
- 7 days ago - Nuwellis Quarterly report: Q3 2026 - Filings
- 7 days ago - Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss - GlobeNewsWire
- 9 days ago - Nuwellis secures exclusive distribution rights for Zorro-Flow - TheFly
- 9 days ago - Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children - GlobeNewsWire